Brylo offers an AI‑driven platform that automates the full gene‑editing workflow, from GWAS‑based target discovery and guide‑RNA design to delivery vector engineering, cell‑therapy construct creation, and regulatory documentation. By integrating quality‑control checks, off‑target risk assessment, and FDA‑compatible CMC report generation, the platform speeds up development for academic labs and biotech companies working on CRISPR‑based therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Gene editing projects are hindered by fragmented computational tools, manual data analysis, and reliance on external vendors, leading to slow target identification, design, and regulatory preparation.
Solution
Brylo provides an integrated, AI-driven platform that automates the entire gene‑editing workflow from target discovery to IND filing. The system combines GWAS‑based gene prioritization, functional genomics, and druggability assessment to identify optimal targets. It then designs guide RNAs, predicts off‑targets, scores base and prime editors, and optimizes multiplexed strategies. Brylo also generates delivery vector constructs (AAV, lentiviral, LNP) with promoter selection, codon optimization, and immunogenicity prediction, and supports cell‑engineering designs for CAR/TCR therapies. The platform includes automated quality‑control checks, genomic stability verification, and regulatory document generation in FDA‑compatible formats, enabling rapid progression from bench to clinic.
Target Audience
Primary customers are academic laboratories, biotech companies developing gene‑editing therapeutics, and research groups requiring end‑to‑end computational support for CRISPR‑based projects.
Features
- GWAS‑driven gene prioritization with pathway analysis and cross‑modality druggability scoring
- AI‑assisted guide RNA design, off‑target risk assessment, and base/prime editor durability prediction
- Automated delivery vector engineering (AAV, lentiviral, LNP) with promoter selection and codon optimization
- Cell‑engineering module for CAR/TCR construct design, single‑cell phenotyping, and batch variability analysis
- Integrated QC pipeline covering off‑target verification, genomic stability, contamination screening, and HLA/STR typing
- Regulatory suite that produces FDA‑formatted CMC documentation, vector diagrams, and batch release records